rel
lack
effici
method
evalu
antisept
antivir
activ
togeth
weak
exist
european
standard
ie
nf
en
underlin
need
seek
new
method
could
allow
precis
evalu
antisept
antivir
activ
chemic
agent
protocol
base
origin
gelbas
filtrat
method
use
inhous
sephadex
tm
column
method
allow
neutral
activ
cytotox
larg
rang
molecul
accord
molecular
size
min
viral
model
use
human
coronaviru
hcov
chosen
increas
medic
interest
ii
potenti
resist
iii
repres
envelop
virus
mention
european
standard
first
protocol
valid
demonstr
fulli
oper
evalu
antivir
antisept
potenti
use
screen
potenti
antisept
molecul
second
chlorhexidin
chx
hexamidin
hxm
assess
potenti
antihcov
antisept
activ
demonstr
clearli
hxm
activ
hcov
ii
chx
show
moder
antihcov
activ
insuffici
antisept
antivir
antisepsi
disinfect
crucial
prevent
environment
spread
viral
infect
inde
effici
specif
treatment
avail
control
infect
furthermor
emerg
virus
associ
diseas
well
nosocomi
viral
infect
becom
import
issu
medic
field
coronavirida
famili
envelop
rna
viru
famili
repres
exampl
issu
sinc
two
human
pathogen
member
famili
identifi
human
coronaviru
strain
hcov
human
coronaviru
strain
hcov
known
respons
larg
proport
common
cold
hamr
procknow
holm
larson
et
al
implic
seriou
diseas
along
newli
identifi
hcov
strain
van
der
hoek
et
al
strain
woo
et
al
inde
virus
recogn
caus
lower
respiratori
tract
infect
van
elden
et
al
also
involv
nosocomi
viral
infect
especi
young
children
neonat
gagneur
et
al
b
moe
et
al
vabret
et
al
elderli
falsey
et
al
nicholson
et
al
immunocompromis
patient
pene
et
al
furthermor
outbreak
sever
acut
respiratori
syndrom
sar
respons
first
worldwid
epidem
centuri
due
newli
discov
coronaviru
sar
associ
coronaviru
sarscov
drosten
et
al
ksiazek
et
al
peiri
et
al
outbreak
led
new
awar
medic
import
coronavirida
famili
anoth
interest
featur
coronavirus
potenti
environment
resist
despit
accept
fragil
envelop
virus
inde
hcov
surviv
h
c
rel
humid
observ
well
hcov
surviv
c
rel
humid
could
account
airborn
transmiss
winter
epidem
hcov
respect
ijaz
et
al
anoth
studi
show
viru
residu
infect
hcov
hcov
respect
day
suspens
phosphat
buffer
salin
pb
c
residu
hcov
infect
h
dri
differ
support
found
hospit
set
ie
aluminium
steril
spong
latex
surgic
glove
sizun
et
al
recent
numer
studi
underlin
import
sarscov
surviv
variou
condit
serum
dilut
sputum
faec
least
h
urin
least
h
sarscov
also
retain
infect
c
room
temperatur
c
least
h
duan
et
al
rabenau
et
al
furthermor
studi
shown
transfer
virus
contamin
host
hand
nasal
mucosa
surfac
environment
surfac
hand
therefor
potenti
contamin
suscept
host
sattar
et
al
winther
et
al
anoth
studi
also
shown
longer
surviv
herpesviru
human
skin
inanim
carrier
ie
stainless
steel
disk
graham
et
al
thu
consid
potenti
resist
hcov
hour
environ
pathogenesi
absenc
specif
treatment
effici
skin
antisepsi
stop
eventu
dissemin
hand
healthcar
worker
meaning
way
fight
viru
transmiss
associ
diseas
fundament
point
evalu
effici
antisepticsdisinfect
atsd
virus
properli
principl
antisept
antivir
activ
evalu
collect
virus
product
test
appropri
defin
precis
contact
time
ii
neutral
product
activ
ie
stop
product
activ
remov
potenti
cytotox
iii
estim
loss
viral
infect
due
product
activ
test
requir
appropri
control
especi
check
absenc
interfer
due
test
viral
infect
effici
neutral
remov
cytotox
also
establish
reproduc
well
defin
condit
eg
contact
time
temperatur
interf
substanc
fig
date
one
european
standard
nf
en
virucid
atsd
activ
test
human
medicin
publish
januari
afnor
specifi
test
method
minimum
requir
establish
virucid
activ
accord
potenti
use
product
test
eg
disinfect
surfac
instrument
hygien
hand
wash
thermochem
disinfect
viru
strain
temperatur
contact
time
interf
substanc
specifi
potenti
use
accord
standard
product
consid
atsd
antivir
activ
induc
loss
infect
least
log
viral
titer
accur
contact
time
paramet
need
extend
improv
antivir
atsd
activ
test
instanc
one
propos
method
european
standard
neutral
product
activ
dilut
productviru
mix
ice
medium
howev
consid
larg
rang
atsd
natur
singl
molecul
mixtur
differ
one
method
alway
reliabl
furthermor
may
lengthen
contact
time
european
standard
suggest
method
base
gelfiltr
techniqu
use
product
sephadex
tm
microspin
tm
column
minicon
concentr
lead
problem
contact
time
separ
capac
cost
supplementari
data
fig
aim
mind
protocol
develop
allow
neutral
min
activ
cytotox
larg
rang
molecul
accord
molecular
size
procedur
also
involv
gelfiltrationbas
method
use
type
sephadex
tm
gel
sephadex
tm
retent
capac
g
mol
g
mol
respect
consist
molecular
mass
atsd
supplementari
data
fig
valid
protocol
establish
potenti
limit
antisept
antivir
activ
two
atsd
chlorhexidin
chx
hexamidin
hxm
test
hcov
minimum
essenti
medium
mem
fetal
calf
serum
fc
trypsineedta
earl
balanc
salt
solut
ebss
trypan
blue
tb
mem
without
glutamin
without
phenol
red
purchas
invitrogen
cergi
pontois
franc
cultur
cell
cm
cell
cultur
flask
human
embryon
pulmonari
epitheli
cell
cell
atcc
kindli
provid
dr
hf
hildebrand
faculti
medicin
lill
franc
grown
mem
supplement
fc
c
humidifi
atmospher
contain
co
split
time
week
cell
grown
cm
cell
cultur
flask
wash
time
phosphat
buffer
salin
pb
ml
trypsineedta
ad
flask
incub
minut
c
co
ml
mem
fc
ad
achiev
cell
dissoci
stock
cell
prepar
cellular
suspens
obtain
trypsin
mix
mem
contain
vv
fc
vv
dimethylsulfoxyd
aliquot
conserv
c
liquid
nitrogen
human
coronaviru
strain
atcc
vr
kindli
provid
dr
sa
sattar
faculti
medicin
ottawa
canada
cultiv
cell
mem
supplement
fc
c
humidifi
atmospher
contain
co
c
shown
optim
growth
temperatur
hcov
bradburn
stock
virus
prepar
infect
cm
cell
cultur
flask
confluent
monolay
cell
much
older
day
confluenc
reach
medium
remov
cell
wash
time
pb
cell
inocul
ml
stock
viru
suspens
dilut
ebss
incub
adsorpt
viru
time
ie
h
c
co
cultur
flask
fill
ml
mem
fc
reincub
c
co
h
cytopath
effect
cpe
ie
cell
lysi
complet
achiev
three
cycl
freezingthaw
min
perform
order
liber
virion
media
centrifug
g
min
elimin
cellular
fragment
supernat
contain
virus
aliquot
cryotub
conserv
c
cell
seed
cellswel
flatbottom
cultur
mem
fc
cell
count
perform
tb
exclus
method
cell
incub
c
co
h
obtain
confluent
monolay
remov
medium
l
fresh
mem
fc
ad
well
cell
infect
multipl
serial
dilut
carri
infect
cell
incub
c
co
day
obtain
optim
cpe
end
incub
period
cell
fix
stain
giemsa
fifti
microliterswel
solut
allow
fix
stain
cell
min
wash
step
tap
water
lwell
giemsa
solut
ad
min
achiev
final
stain
last
wash
step
tap
water
infect
well
count
phasecontrast
invert
microscop
olympu
rungi
franc
viral
titer
cell
cultur
infect
dose
ccid
express
viral
infecti
particl
ml
estim
accord
reed
muench
method
reed
muench
molecul
test
prepar
extemporan
aqueou
solut
filtersteril
filter
chlorhexidin
chx
bisbiguanid
use
wide
antisept
disinfect
use
concentr
mv
ie
mol
l
aqueou
solut
skin
damag
disinfect
mv
ie
mol
l
alcohol
solut
preoper
skin
disinfect
chx
salt
chx
diglucon
use
greater
water
solubl
commerci
use
form
molecular
weight
g
mol
aqueou
solut
colourless
hexamidin
hxm
also
use
wide
skin
disinfect
extern
use
belong
aromat
diamidin
group
hxm
insolubl
water
therefor
hxm
diisethion
salt
solut
water
solubl
limit
g
l
fleurett
also
use
commerci
formul
studi
commerci
formul
hxm
use
mv
ie
mol
l
mv
ie
mol
l
molecular
weight
g
mol
aqueou
solut
colourless
mtt
viabil
assay
nr
cytotox
assay
carri
evalu
cellular
impact
molecul
test
cell
assay
cell
seed
cultur
plate
mem
fc
incub
c
co
h
prior
addit
appropri
dilut
product
test
reincub
h
h
h
mtt
test
modifi
mosmann
protocol
use
mosmann
medium
remov
lwell
pb
l
mtt
solut
mg
ml
pb
ad
h
incub
c
co
l
sodium
dodecyl
sulfat
ad
dissolv
formazan
dark
blue
crystal
produc
reduct
mtt
succin
mitochondri
deshydrogenas
plate
reincub
h
measur
perform
scan
multiwel
spectrophotomet
elisa
reader
multiscan
ex
thermo
fisher
scientif
saint
herblain
franc
use
test
wavelength
nm
refer
wavelength
nm
cell
viabil
valid
proport
produc
quantiti
formazan
crystal
express
inhibitori
concentr
ic
mol
l
nr
assay
perform
accord
modifi
borenfreund
protocol
borenfreund
puerner
aqueou
stock
solut
mg
ml
nr
subject
centrifug
g
min
elimin
eventu
aggreg
prepar
assay
readi
use
solut
nr
g
ml
mem
without
glutamin
without
phenol
red
prepar
extemporan
avoid
fine
precipit
could
form
nr
mix
medium
medium
remov
cell
rins
l
pbswell
prior
addit
lwell
use
nr
solut
plate
reincub
h
c
co
allow
uptak
dye
live
cell
dyemedium
taken
cell
wash
lwell
solut
solut
vv
formaldehyd
vv
mv
cacl
distil
water
releas
nr
accumul
lysosom
live
cell
lwell
b
solut
ad
b
solut
vv
acet
acid
vv
absolut
ethanol
distil
water
quantiti
nr
releas
estim
spectrophotometr
measur
nm
scan
multiwel
spectrophotomet
proport
cytotox
molecul
test
express
cytotox
concentr
cc
mol
l
test
also
perform
solut
chx
hxm
variou
concentr
filtrat
inhous
sephadex
tm
column
evalu
retent
elimin
potenti
cytotox
sephadex
tm
media
rang
crosslink
dextran
gel
variabl
poros
accord
degre
crosslink
properti
base
principl
exclusiondiffus
allow
separ
differ
molecul
accord
molecular
size
manufactur
bead
form
need
suspend
buffer
two
differ
kind
sephadex
tm
use
protocol
sephadex
tm
sephadex
tm
resolut
capac
g
mol
g
mol
respect
accord
manufactur
instruct
sephadex
tm
suspend
minimum
h
room
temperatur
least
time
volum
pb
ie
g
l
equilibr
ph
allow
gel
swell
suspens
steril
autoclav
excess
pb
elimin
obtain
suspens
volum
ratio
sephadex
tm
pb
column
made
ml
syring
stuf
card
cotton
associ
drill
eppendorf
type
ml
microtub
part
steril
autoclav
bodi
syring
fill
ml
steril
sephadex
tm
gel
prepar
describ
system
syring
eppendorf
tube
place
ml
conic
bottom
centrifug
tube
conserv
steril
centrifug
g
min
definit
inhous
sephadex
tm
column
readi
supplementari
data
fig
ninetysixwel
flat
bottom
cultur
plate
seed
cellswel
mem
fc
incub
c
humidifi
atmospher
co
h
obtain
confluent
monolay
day
incub
appropri
dilut
product
test
prepar
distil
water
filtersteril
filter
viral
suspens
hcov
allow
thaw
l
mix
ml
dilut
product
allow
stay
contact
desir
contact
time
separ
virus
product
l
mixtur
place
inhous
sephadex
tm
column
end
contact
time
leav
suffici
time
centrifug
system
place
ml
centrifug
tube
maintain
steril
centrifug
g
min
centrifug
retain
product
accord
molecular
size
kind
sephadex
tm
use
recov
virus
filtrat
viral
titer
evalu
end
point
dilut
method
section
potenti
loss
hcov
infect
estim
differ
viral
titer
posit
control
also
subject
filtrat
inhous
sephadex
tm
column
without
presenc
product
viral
titer
obtain
contact
product
test
desir
contact
time
neutral
filtrat
inhous
sephadex
tm
column
three
type
control
perform
experi
valid
result
nonretent
virus
filtrat
sephadex
tm
column
ii
neutral
potenti
antivir
activ
product
test
iii
elimin
cytotox
european
standard
nf
en
state
differ
viral
titer
treatment
ie
case
gel
filtrat
without
product
test
excess
log
assess
nonretent
virus
eg
hcov
viral
suspens
mix
steril
distil
water
contact
time
defin
experi
filter
inhous
sephadex
tm
column
titrat
describ
section
neutral
assay
perform
filtrat
l
solut
test
inhous
sephadex
tm
column
l
filtrat
mix
l
viral
suspens
mixtur
inocul
cell
monolay
viral
titer
obtain
equival
viral
titer
without
filtrat
ie
log
differ
sinc
product
retain
column
experi
also
verifi
filtrat
influenc
viru
infect
cytotox
control
also
carri
experi
complement
mtt
nr
assay
undertaken
previous
control
perform
filtrat
l
product
test
filtrat
inocul
cell
day
incub
cell
monolay
observ
invert
microscop
sign
cytotox
visibl
retent
molecul
test
inhous
sephadex
tm
column
also
confirm
uvvis
spectrophotometri
rang
dilut
assay
establish
specif
spectrophotometr
paramet
maximum
absorpt
wavelength
max
molar
absorpt
coeffici
detect
limit
molecul
dilut
prepar
distil
water
mimic
test
condit
spectra
perform
uvvis
spectrophotomet
safa
monaco
within
nm
window
calibr
curv
max
f
c
establish
determin
molar
absorpt
coeffici
molecul
differ
dilut
product
test
prepar
distil
water
filter
inhous
sephadex
tm
column
absorb
measur
max
determin
residu
concentr
valid
process
statist
analysi
differ
step
undertaken
use
statview
version
test
maximum
accept
risk
assess
homogen
column
ie
volum
gel
first
centrifug
volum
filtrat
second
centrifug
kolmogorovsmirnov
test
use
assur
distribut
normal
independ
test
batch
bartlett
test
use
compar
varianc
case
varianc
homogen
anova
test
use
compar
mean
differ
batch
case
nonhomogen
varianc
nonparametr
test
kruskallw
use
compar
averag
final
correl
studi
use
fisher
transform
realis
estim
whether
associ
gel
volum
either
filtrat
volum
residu
concentr
filtrat
sephadex
tm
uvspectrophotometri
regress
analysi
f
c
carri
establish
specif
spectrophotometr
paramet
molecul
test
specifi
section
two
centrifug
step
need
prepar
optim
column
ml
gel
whether
sephadex
tm
sephadex
tm
ii
filter
drugviru
mixtur
achiev
neutral
step
retent
molecul
test
nonretent
virus
homogen
quantiti
filtrat
differ
speed
time
centrifug
test
best
paramet
determin
min
g
first
centrifug
min
g
second
centrifug
homogen
gel
volum
obtain
first
centrifug
ii
filtrat
volum
obtain
second
centrifug
first
establish
independ
batch
tabl
uvvis
spectrophotometr
paramet
molecul
test
retent
rate
molecul
test
suspend
steril
distil
water
ph
calibr
curv
establish
molecul
uvvis
spectrophotomet
within
nm
wavelength
window
concentr
test
rang
mol
l
mol
l
except
trypan
blue
tb
neutral
red
nr
concentr
rang
mol
l
mol
l
mol
l
mol
l
respect
regress
analys
perform
determin
specif
spectrophotometr
paramet
linear
limit
mol
l
ii
minimum
detect
limit
mol
l
within
limit
iii
specif
maxim
absorpt
wavelength
max
nm
iv
specif
molar
absorpt
coeffici
l
mol
cm
retent
rate
see
formula
section
molecul
specifi
type
sephadex
tm
media
indic
ie
tb
chlorhexidin
chx
retent
rate
sephadex
tm
nr
hexamidin
hxm
retent
rate
sephadex
tm
ci
correspond
initi
concentr
concentr
filtrat
absorpt
wavelength
use
estim
retent
rate
specifi
time
necessari
specif
spectrophometr
paramet
molecul
test
retent
rate
column
sephadex
tm
gel
statist
analysi
use
statview
v
section
retent
rate
dye
molecul
measur
tb
g
mol
sephadex
tm
nr
g
mol
sephadex
tm
determin
rate
spectrophotometr
paramet
tb
nr
tabl
establish
measur
absorb
concentr
rang
mol
l
mol
l
tb
mol
l
mol
l
nr
follow
regress
analysi
section
residu
concentr
filtrat
estim
measur
absorb
uvvis
calcul
retent
rate
accord
formula
retent
rate
ci
cf
cf
ci
initi
concentr
concentr
filtrat
cf
final
concentr
residu
concentr
filtrat
retent
rate
obtain
tb
filtrat
sephadex
tm
filtrat
tb
solut
mol
l
mol
l
commerci
concentr
respect
nr
solut
either
mol
l
mol
l
filtrat
sephadex
tm
concentr
detect
threshold
thu
retent
rate
obtain
filtrat
nr
solut
mol
l
mol
l
found
within
rang
l
gel
volum
first
centrifug
signific
variat
filtrat
volum
retent
rate
experi
gel
volum
includ
within
limit
basic
inhous
sephadex
tm
column
retain
product
virus
accord
european
standard
nf
en
afnor
differ
viral
titer
treatment
ie
filtrat
exceed
log
ensur
nonretent
virus
independ
experi
sephadex
tm
type
contact
time
test
perform
hcov
stock
suspens
dilut
steril
distil
water
filter
inhous
sephadex
tm
column
viral
titer
compar
without
filtrat
tabl
sephadex
tm
log
differ
viral
titer
contact
time
min
min
min
respect
n
contact
time
sephadex
tm
log
differ
viral
titer
contact
time
min
min
min
min
min
respect
n
contact
time
consequ
sephadex
tm
column
sephadex
tm
type
retain
hcov
induc
loss
infect
elimin
cytotox
crucial
control
inocul
filtrat
onto
cell
allow
assess
antivir
tabl
elimin
potenti
cytotox
filtrat
inhous
sephadex
tm
column
inhibitori
concentr
cytotox
concentr
chlorhexidin
chx
hexamidin
hxm
without
filtrat
cell
evalu
methyl
thiazol
tetrazolium
mtt
assay
neutral
red
nr
assay
respect
bold
chx
solut
mol
l
mol
l
ii
hxm
solut
mol
l
mol
l
filtrat
inhous
sephadex
tm
sephadex
tm
column
respect
evalu
result
express
mol
l
repres
averag
independ
experi
ci
h
h
h
chx
without
filtrat
mol
l
mol
l
without
filtrat
without
filtrat
mol
l
mol
l
without
filtrat
mol
l
mol
l
activ
elimin
eventu
cellular
impact
product
cell
mtt
nr
assay
carri
determin
ic
cc
respect
ic
cc
chx
hxm
solut
without
filtrat
first
determin
cell
section
ic
cc
chx
hxm
solut
differ
concentr
filtrat
inhous
sephadex
tm
column
determin
make
sure
elimin
eventu
cytotox
filtrat
inhous
sephadex
tm
column
experi
repeat
time
independ
find
ic
cc
correspond
averag
result
experi
shown
tabl
ic
chx
cell
mol
l
mol
l
mol
l
h
h
h
respect
cc
mol
l
mol
l
mol
l
h
h
h
respect
filtrat
chx
solut
mol
l
mol
l
sephadex
tm
column
cc
ic
mol
l
accord
detect
limit
method
except
h
ic
cc
mol
l
filtrat
mol
l
chx
solut
experi
carri
hxm
ic
hxm
without
filtrat
mol
l
mol
l
mol
l
h
h
h
respect
cc
mol
l
mol
l
mol
l
h
h
h
respect
filtrat
hxm
solut
mol
l
sephadex
tm
column
ic
cc
mol
l
except
h
cc
mol
l
tabl
nonretent
hcov
inhous
sephadex
tm
column
result
express
cell
cultur
infect
dose
repres
averag
viral
titer
least
independ
experi
assay
allow
evalu
nonretent
human
coronaviru
hcov
sephadex
tm
type
contact
time
test
viral
suspens
dilut
steril
distil
water
specifi
contact
time
filtrat
inhous
sephadex
tm
column
inocul
cell
nd
determin
sephadex
tm
sephadex
tm
without
filtrat
filtrat
differ
without
filtrat
filtrat
differ
n
n
n
n
n
n
nd
nd
nd
n
n
n
nd
nd
nd
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
hxm
solut
mol
l
also
assay
ic
cc
shown
close
without
filtrat
tabl
thu
retent
shown
incomplet
concentr
consequ
inhous
sephadex
tm
column
clearli
demonstr
effici
elimin
cytotox
solut
concentr
mol
l
dye
molecul
tb
nr
specif
spectrophotometr
paramet
retent
rate
chx
hxm
determin
use
uvvis
spectrophotometri
section
test
differ
dilut
chx
ie
mol
l
mol
l
specif
spectrophotometr
paramet
chx
establish
tabl
two
maximum
absorpt
wavelength
max
nm
nm
observ
molecular
absorpt
coeffici
l
cm
mol
l
cm
mol
respect
coeffici
obtain
mean
regress
analysi
realiz
statview
n
measur
p
relat
f
c
linear
mol
l
max
nm
correl
coeffici
mol
l
max
nm
correl
coeffici
detect
limit
mol
l
max
result
consist
data
literatur
bonazzi
et
al
european
pharmacopeia
ha
cheung
havlikova
et
al
hebert
et
al
uv
detect
especi
high
perform
liquid
chromatographi
done
either
nm
nm
nm
retent
rate
chx
solut
evalu
differ
concentr
inhous
sephadex
tm
column
tabl
three
independ
experi
realiz
duplic
n
retent
rate
observ
chx
solut
mol
l
mol
l
chx
solut
mol
l
complet
retain
retent
rate
nm
nm
way
hxm
assay
mol
l
mol
l
tabl
max
observ
nm
associ
molar
absorpt
coeffici
l
cm
mol
linear
relationship
mol
l
n
p
correl
coeffici
detect
limit
hxm
uvvis
spectrophotometri
mol
l
data
consist
european
pharmacopeia
recommend
hxm
detect
nm
european
pharmacopeia
hexamidin
retent
rate
inhous
sephadex
tm
column
evalu
hxm
mol
l
mol
l
molecul
retent
limit
reach
hxm
mol
l
retent
rate
could
determin
accur
residu
concentr
linear
limit
detect
ie
mol
l
thu
retent
rate
verifi
neutral
control
essenti
assess
stop
potenti
antivir
activ
respect
defin
contact
time
furthermor
test
ensur
interfer
filtrat
viru
infect
fig
recommend
european
standard
nf
en
differ
viru
control
neutral
control
excess
log
section
neutral
control
done
independ
experi
product
concentr
contact
time
neutral
assay
perform
chx
mol
l
mol
l
mean
log
differ
obtain
n
independ
assay
concentr
fig
evalu
antisept
antivir
activ
chx
hxm
hcov
figur
show
reduct
viral
titer
obtain
action
chlorhexidin
chx
hexamidin
hxm
differ
concentr
specifi
contact
time
repres
reduct
human
coronaviru
hcov
titer
obtain
action
chx
mol
l
mol
l
b
repres
reduct
hcov
titer
obtain
action
hxm
mol
l
bold
line
graph
repres
threshold
reduct
reach
pretend
antivir
antisept
activ
respect
assay
carri
hxm
mol
l
mean
log
differ
obtain
n
independ
assay
thu
potenti
antivir
antisept
activ
correctli
neutral
molecul
concentr
test
furthermor
interfer
viru
infect
observ
assay
perform
describ
section
assay
correspond
evalu
potenti
at
antihcov
activ
one
concentr
molecul
test
one
contact
time
assay
repeat
independ
time
includ
necessari
control
ie
posit
viru
control
nonretent
hcov
effici
neutral
elimin
cytotox
valid
test
fig
chx
test
concentr
mol
l
mol
l
concentr
test
differ
contact
time
ie
min
min
min
min
fig
log
reduct
viral
titer
induc
action
chx
mol
l
min
min
min
min
respect
concentr
mol
l
chx
induc
reduct
contact
time
min
min
min
min
respect
accord
european
standard
nf
en
log
reduct
lower
log
even
chx
certain
activ
hcov
at
antihcov
properti
condit
hxm
show
even
wors
activ
hcov
mol
l
induc
reduct
log
log
min
min
contact
time
respect
far
threshold
recommend
european
standard
fig
given
result
concentr
mol
l
contact
time
min
min
test
fight
viral
infect
atsd
seem
crucial
consid
rel
lack
effici
treatment
vaccin
avail
ii
risk
outbreak
new
viral
pathogen
thu
essenti
evalu
antivir
activ
properli
reliabl
major
item
propos
european
standard
nf
en
follow
contact
time
ii
maximum
log
differ
control
viral
titer
section
valid
assay
iii
log
reduct
assess
antisept
antivir
activ
drug
test
howev
paramet
standard
need
intensifi
especi
neutral
method
choic
viru
strain
inde
neutral
step
fundament
ensur
precis
contact
time
ii
remov
potenti
cytotox
inocul
cell
could
involv
confus
product
activ
estim
european
standard
nf
en
two
global
techniqu
propos
dilut
ice
medium
gel
filtrat
techniqu
involv
differ
problem
lengthen
contact
time
effici
also
cost
dilut
method
neutral
step
requir
min
inconsist
recommend
contact
time
differ
applic
mention
european
standard
also
contact
time
suit
potenti
use
product
eg
min
mandatori
contact
time
test
disinfect
surfac
instrument
facult
time
min
min
min
practic
surfac
would
rare
disinfect
min
furthermor
dilut
alway
shown
effici
instanc
ic
cc
chx
cell
higher
mol
l
h
h
h
even
dilut
mol
l
solut
chx
european
standard
recommend
dilut
effici
solut
remain
cytotox
nonetheless
european
standard
also
propos
gel
filtrat
techniqu
neutral
product
activ
use
sephadex
tm
ultrafiltr
system
minicon
millipor
prepack
column
microspin
tm
hr
major
problem
method
lengthen
contact
time
inde
need
least
min
achiev
neutral
step
sometim
min
depend
techniqu
furthermor
separ
capac
well
adapt
molecular
mass
atsd
anoth
drawback
minicon
concentr
nonsteril
devic
bear
steril
use
filter
virus
american
standard
astm
e
recommend
also
gel
filtrat
method
use
sephadex
tm
sephacryl
tm
superfin
neutral
virucid
activ
astm
virucid
efficaci
criterion
astm
standard
log
reduct
astm
procedur
close
one
develop
howev
centrifug
time
elimin
void
ii
separ
product
test
virus
min
instead
min
inhous
sephadex
tm
column
first
gel
propos
sephadex
tm
well
adapt
retent
capac
atsd
molecular
mass
supplementari
data
fig
unfortun
sold
anymor
gel
propos
sephacryl
tm
superfin
commerci
suspens
form
distil
water
contain
ethanol
conserv
presenc
ethanol
could
affect
test
emphas
effect
atsd
test
lead
overestim
product
activ
cost
also
higher
inhous
sephadex
tm
column
retent
capac
well
adapt
supplementari
data
fig
choic
viru
strain
could
also
discuss
recent
question
ijaz
rubino
european
standard
nf
en
propos
virus
polioviru
type
adenoviru
type
bovin
parvoviru
haden
strain
polioviru
chosen
potenti
high
resist
chemic
take
account
worldwid
program
poliomyel
erad
legitimaci
choic
question
way
choic
parvoviru
adenoviru
arguabl
although
parvoviru
respons
seriou
rare
maternofoet
infect
also
infect
immunocompromis
patient
andor
patient
haemolyt
anaem
disord
shown
frequent
nosocomi
pathogen
interest
howev
lie
high
resist
chemic
wide
rang
ph
temperatur
potenti
blood
transmiss
rout
morinet
et
al
howev
strain
use
european
standard
bovin
parvoviru
question
repres
contrast
human
serovar
adenoviru
interest
notabl
respons
mild
upper
respiratori
tract
infect
ophthalmolog
infect
also
gastroenter
particularli
newborn
young
children
caus
rare
seriou
mortal
infect
immunodepress
patient
especi
bonemarrow
transplant
patient
carret
le
faou
also
probabl
chosen
high
resist
environment
condit
virus
nake
virus
alway
repres
major
risk
encount
commun
hospit
set
establish
protocol
first
challeng
elabor
uniqu
protocol
sephadex
tm
gel
order
make
assay
easier
perform
best
paramet
need
centrifug
step
determin
conserv
steril
entir
assay
paramet
first
valid
statist
analysi
without
drug
test
ensur
repeat
column
yield
fix
accept
limit
protocol
thu
protocol
made
perform
neutral
min
better
method
therefor
differ
viru
propos
european
standard
chosen
hcov
medic
interest
also
presenc
annex
b
european
standard
nf
en
potenti
contamin
surfac
instrument
hand
furthermor
belong
envelop
virus
absent
standard
may
behav
differ
nake
virus
action
atsd
also
chosen
rel
resist
differ
condit
take
account
envelop
virus
often
consid
fragil
assay
show
nonretent
hcov
inhous
sephadex
tm
column
whether
import
ph
highlight
import
caus
variabl
result
ie
viral
titer
difficulti
experienc
mainli
sephadex
tm
need
excess
solvent
ie
pb
swell
reach
neutral
also
steril
distil
water
owe
steril
process
often
involv
acidif
could
due
high
sensit
hcov
ph
rapid
loss
infect
aggreg
virion
shown
ph
c
wherea
viru
quit
stabl
ph
c
sturman
et
al
ph
verifi
adjust
neutral
allow
standard
protocol
test
protocol
antihcov
activ
chx
hxm
evalu
wide
use
molecular
size
allow
test
type
sephadex
tm
first
shown
retain
inhous
sephadex
tm
column
potenti
cytotox
remov
furthermor
neutral
techniqu
interfer
viru
infect
stage
limit
gel
filtrat
method
concentr
product
test
appear
concentr
mol
l
molecul
retain
complet
phenomenon
column
overload
howev
seem
seriou
sinc
product
use
rare
concentr
notabl
potenti
toxic
stage
anticoronaviru
activ
chx
hxm
could
assess
thu
result
demonstr
clearli
hxm
atsd
activ
hcov
knowledg
littl
data
concern
possibl
atsd
antivir
activ
hxm
avail
literatur
addit
result
show
despit
activ
hcov
chx
could
pretend
atsd
activ
hcov
test
condit
accord
european
standard
howev
accord
american
standard
virucid
efficaci
criterion
log
reduct
chx
atsd
antivir
activ
mol
l
min
activ
realli
repres
field
use
condit
studi
chx
shown
ineffici
nake
virus
bernstein
et
al
kawana
et
al
narang
codd
wood
payn
ii
effici
concentr
mol
l
envelop
virus
activ
depend
virus
test
test
condit
bernstein
et
al
kawana
et
al
platt
bucknal
tyler
ayliff
wood
payn
instanc
chx
reduc
herp
simplex
viru
viral
titer
log
suspens
test
min
kawana
et
al
wood
payn
log
dri
sampl
hsv
min
tyler
ayliff
also
import
note
antisept
chemic
use
mix
differ
molecul
diluent
often
ethanol
virucid
activ
instanc
differ
formul
contain
chlorhexidin
diglucon
assay
at
antivir
activ
respond
american
virucid
criterion
test
mv
ie
mol
l
cetrimid
mv
howev
induc
log
reduct
hcov
viral
titer
test
mv
ie
mol
l
cetrimid
mv
ethanol
sattar
et
al
data
show
test
condit
must
taken
account
compar
antisept
antivir
activ
ie
suspens
carrier
test
presenc
interf
substanc
chosen
criterion
assess
virucid
activ
possibl
misestim
product
activ
due
differ
test
condit
make
essenti
determin
best
paramet
close
possibl
real
condit
applic
valid
protocol
first
step
improv
antivir
atsd
activ
evalu
still
long
way
go
get
perfect
test
expect
goal
method
elimin
least
reduc
lowest
possibl
level
concentr
product
test
order
evalu
precis
contact
time
antivir
potenti
without
toxic
host
cell
without
modifi
viru
infect
even
protocol
valid
mean
vitro
suspens
test
could
extrapol
vitro
carrier
test
vivo
ex
vivo
protocol
protocol
use
support
plastic
steel
disk
sattar
et
al
fingertip
sattar
ansari
disk
human
skin
remov
plastic
surgeri
graham
et
al
carrier
test
recommend
differ
standard
simul
best
field
situat
virus
dri
often
embed
organ
materi
limit
access
atsd
thu
potenti
activ
ex
vivo
protocol
import
test
antivir
at
activ
either
pathogen
virus
toxic
compound
healthi
ethic
reason
could
assay
vivo
protocol
use
instanc
fingertip
volunt
furthermor
also
use
evalu
pathogen
surviv
human
skin
carrier
test
need
dilut
step
recov
dri
viru
suspens
support
action
chemic
dilut
step
play
role
neutral
ensur
contact
time
could
achiev
addit
cultur
medium
chemic
could
neutral
specif
product
activ
eg
use
sodium
thiosulf
neutral
povidoneiodin
howev
diluent
could
toxic
cell
thu
method
could
appli
case
elimin
chemic
neutral
inocul
viral
suspens
safe
potenti
also
found
astm
standard
e
studi
describ
global
method
chemic
neutral
ensur
nonretent
virus
mainten
infect
min
therefor
method
could
use
test
chemic
differ
applic
surfac
water
disinfect
could
use
human
medic
field
well
veterinari
industri
eg
food
industri
applic
also
screen
antisept
antivir
potenc
new
drug
